Filtered By:
Specialty: Hematology
Drug: Dexamethasone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 241 results found since Jan 2013.
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283490. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory (RR)MM r...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Enrique M Ocio Yvonne A Efebera Roman H ájek Jan Straub Vladimir Maisnar Jean-Richard Eveillard Lionel Karlin Mar ía-Victoria Mateos Albert Oriol Vincent Ribrag Paul G Richardson Stefan Norin Jakob Oberm üller Nicolaas A Bakker Lud ěk Pour Source Type: research
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283490. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory (RR)MM r...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Enrique M Ocio Yvonne A Efebera Roman H ájek Jan Straub Vladimir Maisnar Jean-Richard Eveillard Lionel Karlin Mar ía-Victoria Mateos Albert Oriol Vincent Ribrag Paul G Richardson Stefan Norin Jakob Oberm üller Nicolaas A Bakker Lud ěk Pour Source Type: research
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283490. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory (RR)MM r...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Enrique M Ocio Yvonne A Efebera Roman H ájek Jan Straub Vladimir Maisnar Jean-Richard Eveillard Lionel Karlin Mar ía-Victoria Mateos Albert Oriol Vincent Ribrag Paul G Richardson Stefan Norin Jakob Oberm üller Nicolaas A Bakker Lud ěk Pour Source Type: research
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283490. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory (RR)MM r...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Enrique M Ocio Yvonne A Efebera Roman H ájek Jan Straub Vladimir Maisnar Jean-Richard Eveillard Lionel Karlin Mar ía-Victoria Mateos Albert Oriol Vincent Ribrag Paul G Richardson Stefan Norin Jakob Oberm üller Nicolaas A Bakker Lud ěk Pour Source Type: research
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283490. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory (RR)MM r...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Enrique M Ocio Yvonne A Efebera Roman H ájek Jan Straub Vladimir Maisnar Jean-Richard Eveillard Lionel Karlin Mar ía-Victoria Mateos Albert Oriol Vincent Ribrag Paul G Richardson Stefan Norin Jakob Oberm üller Nicolaas A Bakker Lud ěk Pour Source Type: research
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283490. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory (RR)MM r...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Enrique M Ocio Yvonne A Efebera Roman H ájek Jan Straub Vladimir Maisnar Jean-Richard Eveillard Lionel Karlin Mar ía-Victoria Mateos Albert Oriol Vincent Ribrag Paul G Richardson Stefan Norin Jakob Oberm üller Nicolaas A Bakker Lud ěk Pour Source Type: research
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Haematologica. 2023 Aug 24. doi: 10.3324/haematol.2022.282624. Online ahead of print.ABSTRACTTo improve patient outcomes in the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient prognosis becomes worse after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) r...
Source: Haematologica - August 23, 2023 Category: Hematology Authors: Paul G Richardson Brian G Durie Laura Rosi ñol Maria-Victoria Mateos Angela Dispenzieri Philippe Moreau Shaji Kumar Noopur Raje Nikhil Munshi Jacob P Laubach Peter O'Gorman Elizabeth O'Donnell Peter Voorhees Thierry Facon Joan Blad é Sagar Lonial Aurore Source Type: research
